Clinical Trial Update: A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial of GNC-035 for relapsed/refractory chronic lymphocytic leukemia (and other hematological malignancies) is listed as active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• GNC-035

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING